BioWorld Science

Oct. 28, 1997

View Archived Issues

U.S. Bioscience: Q3 1997 highlights

Read More

Sonus: Q3 1997 highlights

Read More

Lamisil's safety profile confirmed

Read More

39th PDR Annual General Meeting

Read More

OXiGENE: Q3 1997 highlights

Read More

Spotlight on tryptase inhibitors for asthma

Read More

Novel antiangiogenic agent with oral activity in animal model of breast cancer

Read More

Mechanism of action and in vivo antitumor efficacy reported for CS-682

Read More

Company Profile: Apoptogen

Read More

U.S. patent allowed for Hyal's lead product formulations

Read More

DAB-720: a new EGF receptor TK inhibitor from Mitsubishi Chemical

Read More

Antitumor activity of LC-9018 correlated with cytokine production

Read More

Preclinical studies on FK-317 presented at cancer meeting

Read More

Endorex raises funds for clinical testing of antitumor drugs

Read More

New MRI contrast agent available in Europe

Read More

NIH awards Vaxcel two grants for vaccine research

Read More

Oxford BioMedica acquires novel anticancer technology

Read More

Effexor XR cleared by FDA

Read More

Ferrer to distribute Orthovisc in Spain, Portugal

Read More

Sibia's TBA technology licensed to Neurocrine Biosciences

Read More

Structure of NO-producing enzyme solved

Read More

Shaman issued U.S. patent for antidiabetic compounds

Read More

VZIG study in postherpetic neuralgia stopped; chickenpox study continues

Read More

Cangene to manufacture new formulation of NABI's H-BIG

Read More

Alexion reports phase I/II and IIa results for C5 inhibitor

Read More

Research team identifies effector of morphological changes during apoptosis

Read More

Dyax and Tularik establish drug discovery collaboration

Read More